In melanoma, mutations in the IFNγ-JAK-STAT pathway drive resistance to checkpoint inhibitors but, paradoxically, increase tumor sensitivity to oncolytic VSV treatment [128]. The gene discussed is IFNG; the disease is neoplasm.